| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | -0.024 | 0.5 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.022 | 0.5 |
| mRNA | AP-24534 | GDSC1000 | pan-cancer | AAC | -0.021 | 0.5 |
| mRNA | 681640 | GDSC1000 | pan-cancer | AAC | 0.024 | 0.5 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.021 | 0.5 |
| mRNA | Bexarotene | FIMM | pan-cancer | AAC | 0.1 | 0.5 |
| mRNA | CID-5951923 | CTRPv2 | pan-cancer | AAC | -0.024 | 0.5 |
| mRNA | BRD-K19103580 | CTRPv2 | pan-cancer | AAC | 0.024 | 0.5 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | -0.047 | 0.5 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | -0.028 | 0.5 |